NCT06337162 (HCC) is a Phase 1 clinical trial of INCB099280 in Hepatocellular Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT06337162?

NCT06337162 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT06337162?

Interventions in NCT06337162: INCB099280.

What condition does NCT06337162 study?

NCT06337162 studies Hepatocellular Carcinoma.

Is NCT06337162 still recruiting?

NCT06337162 is currently withdrawn. Last updated 9 August 2024.

Last reviewed 2024-08-09 · How we verify

NCT06337162: HCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

Withdrawn Phase 1 Last updated 9 August 2024

What this trial tests

Phase 1 trial testing INCB099280 in Hepatocellular Carcinoma. Withdrawn.

Timeline

1 May 2024

Primary endpoint
1 May 2027

1 September 2028

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 May 2024
Primary completion	1 May 2027
Estimated completion	1 September 2028
Sites	1 location across United States

Drugs / interventions tested

INCB099280 — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.
Marzi L, Mega A, Turri C, Gitto S, et al · · 2024 · cited 4× · PMID 39519230 · DOI 10.3390/ijms252111676
Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates.
Yu D, Chen H, Wang L. · · 2025 · cited 1× · PMID 40682511 · DOI 10.1002/cnr2.70244
Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.
Kapelanski-Lamoureux A, Lazaris A, Meti N, Metrakos P. · · 2025 · PMID 41375071 · DOI 10.3390/cancers17233870

Verify or expand the search:

Other trials of INCB099280

Trials testing the same drug.

NCT06309394 — A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 i · Phase 1 · completed
NCT05949632 — A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors · Phase 1, PHASE2 · terminated
NCT06039384 — A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation · Phase 1 · terminated
NCT05879822 — A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive · Phase 2 · active not recruiting
NCT05888844 — A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma · Phase 2 · active not recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06337162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 9 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06337162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing